On behalf of the organizing and scientific committees, it is a great pleasure to welcome you to the 23rd Annual Scientific
Symposium of the Hong Kong Cancer Institute: Immuno-Oncology Hong Kong 2018. This biannual symposium is co-organized
by the Department of Clinical Oncology and the Hong Kong Cancer Institute in conjunction with Partner State Key Laboratory
of Oncology in South China at the Chinese University of Hong Kong.
Cancer treatment is fast changing. With advent of molecular targeted therapy and immuno--oncology, we will be able to transform advanced stage cancer into a chronic illness. “Immuno-Oncology Hong Kong 2018” aims at providing an international platform for all clinical and preclinical, scientists, academia, healthcare professionals and pharmaceutical companies to share and discuss cancer immunotherapeutic strategies in Asia. The two-day regional meeting focuses on topics including basic biology, early drug development, biomarkers and site-specific applications and challenges in lung cancer, central nervous system tumor, head & neck cancer, sarcoma and uncommon malignancy, genitourinary, gynecological, haematological, gastrointestinal & hepatocellular cancers. Pioneer leaders from Asia, Europe and United States will gather in Hong Kong to share their insightful experience and future prospective. Transfer of knowledge is the best way to start this era of immuno-oncology.
We expect to attract over 500 participants coming from across the world. Your participation and contribution are pivotal to our cause. We hope this meeting will bring you new insights and knowledge into the development of immunotherapies for cancer patients.
Last but not least, we look forward to welcoming you to Immuno-Oncology Hong Kong 2018, 10 - 11 November at JW Marriott Hotel, Hong Kong.